Ads
related to: atopic dermatitis treatment- Start Saving On Your Rx
Download A $0 Copay Savings
Card For Your Rx. Terms Apply.
- Activate Your Copay Card
Activate Your Copay Savings Card
For Your Rx. Terms Apply
- Prescribing Information
Learn About An FDA-Approved Rx For
Moderate-To-Severe Eczema.
- Tell Us Your Story
Patients Can Share Their Experience
About Taking This Rx Eczema Pill.
- Rx Option For Teens 12-17
Learn About An Eczema Rx Option
For Patients 12 Years & Older
- Locate A Doctor Near You
Visit The Site To Find A Doctor Who
Treats Moderate-To-Severe Eczema.
- Start Saving On Your Rx
Search results
J&J to acquire experimental eczema drug for $1.25B
NJBIZ· 9 hours agoJohnson & Johnson plans to pay $1.25 billion for the rights to an experimental eczema treatment. The New Brunswick-based pharma giant announced the...
Tapinarof Cream Effective For AD, Down to Age 2 Years
Medscape· 2 days agoResults from two phase 3 trials showed that topical tapinarof, once a day, was effective and safe in patients with atopic dermatitis as young as 2 years old.
Rapid Rx Quiz: New Agents for Treating Atopic Dermatitis
Medscape· 2 days agoTopical corticosteroids were the initial treatment option for atopic dermatitis (AD) beginning in...
...Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis - Johnson & Johnson...
Benzinga· 2 days agoJ&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on ...
J&J acquires experimental skin disorder drug for $1.25 billion
Reuters via Yahoo News· 2 days agoJ&J will acquire a unit of Numab, backed by the parent of Danish drugmaker Novo Nordisk, to gain...
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 8 hours agoJakavi royalties beat the Zacks Consensus Estimate of $86 million. Incyte also receives royalties...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days ago- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si ...
Dupilumab: Future Treatment for Pediatric Alopecia Areata?
Medscape· 2 days agoChildren with concomitant atopic dermatitis (AD) and alopecia areata (AA) who were treated with...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI...
Benzinga· 1 hour agoREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
J&J gains another bispecific antibody with $1.25B skin drug buy
BioPharma Dive via Yahoo Finance· 3 days agoIn a statement, J&J said NM26 has the potential to offer “distinctive benefits” versus existing ...
